A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

NCT07062978 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

278

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis at High Risk of Fracture

Interventions

DRUG: QL1206
DRUG: Prolia®

Sponsor

Qilu Pharmaceutical Co., Ltd.